id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-016419-v1f6dx3e	Gupta, Varsha	Production of Recombinant Pharmaceutical Proteins	2016-10-23		.txt	text/plain	9648	602	50	Usage of recombinant DNA technology for large-scale production of proteins requires ample amount of time, labor, and resources, but it also offers many opportunities for economic growth. The recombinant proteins approved by FDA are obtained either from Escherichia coli or other prokaryotes; from Saccharomyces cerevisiae or other fungal species; from insect cells , mammalian cells , or human cells ; or from transgenic plants or animals. Their advantages are low cost, high mass production, scale-up, lack of human pathogens , and addition of eukaryotic PTMs. The fi rst recombinant protein obtained in 1986 from tobacco plants was human growth hormone . The vector can be modifi ed to express genes for insulin (tomato) or Hep-B surface antigen (HBsAg) for recombinant therapeutics providing a human glycosylation pattern have increased attention, and the efforts are being made for the development of novel glycoengineered cell lines for production of fully glycosylated protein therapeutic.	./cache/cord-016419-v1f6dx3e.txt	./txt/cord-016419-v1f6dx3e.txt